Start-up: Pfizer funds ex-workers
Enlarge image


Start-up: Pfizer funds ex-workers

06.11.2012 - Ziarco has raised €21.1m in a series A financing round. The start-up from four former Pfizer colleagues gets the money from their former employer.

Ziarco Pharma Ltd. from Canterbury secured €21.1m (GBP16.8m) in a series A financing round. Investors are US venture fund Biotechnology Value Fund L.P. and other affiliates of BVF Partners L.P. (“BVF”) as well as Pfizer Venture Investments (“PVI”). Ziarco is a new clinical-stage biotechnology company founded by President and CEO Mike Yeadon, a former Vice President and Chief Scientific Officer of Pfizer’s Allergy and Respiratory Research Unit in Sandwich. Together with three former Pfizer colleagues, he directs the start-up which aims to develop innovative therapeutics targeting inflammatory and allergic diseases. One of the peers, CSO Steve Liu, claims that the most advanced clinical programme, ZPL-3893787 – a histamine H4 receptor (H4R) antagonist – could potentially be used to treat several major diseases, including asthma, allergic rhinitis, pain and a variety of inflammatory skin conditions. This programme is included in a deal made by Ziarco and Pfizer Inc. that promises the start-up exclusive worldwide rights to commercialise a range of clinical, preclinical and research assets. In return, Pfizer will receive equity as well as certain product-based milestone and royalty payments.

The lead compound of the H4R antagonist programme has completed a Phase I multiple ascending dose study. Other programmes in various stages of development include a clinical stage cytosolic phosholipase A2 (cPLA2) inhibitor, histamine H3 receptor antagonists possessing CNS-sparing properties as well as early-stage spleen tyrosine kinase (SYK) inhibitor molecules suitable for topical administration.



09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • WILEX (D)2.20 EUR10.00%
  • DEINOVE (F)6.85 EUR7.54%


  • IMMUPHARMA (UK)28.50 GBP-12.98%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.08 EUR43.7%
  • OREXO (S)65.25 SEK40.9%
  • ZEALAND PHARMA (DK)155.00 DKK26.0%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • IMMUPHARMA (UK)28.50 GBP-30.1%


  • KARO BIO (S)43.10 SEK5221.0%
  • CHRONTECH PHARMA (S)0.34 SEK325.0%
  • GALAPAGOS (B)38.85 EUR237.5%


  • NEOVACS (F)0.72 EUR-76.7%
  • BIOTEST (D)19.00 EUR-74.8%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 09.10.2015